VentriPoint Diagnostics Ltd.
VentriPoint Diagnostics Ltd.
Your view on VPTDF
Overview
What the company does, where it operates, and who runs it.
About VentriPoint Diagnostics Ltd.
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Hugh MacNaught
- Headquarters
- 18 Hook Avenue, Toronto, ON, CA
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Hugh MacNaught
- Headquarters
- 18 Hook Avenue, Toronto, ON, CA
Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease worldwide.
The company offers Ventripoint Medical System (VMS), a medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient's heart chambers; VMS+ software for use in creating three-dimensional model of the heart chamber using echocardiograms and magnetic resonance imaging images; and obtain reproducible, accurate volumetric measurement, and ejection fraction.
It also develops a suite of applications for various heart diseases and imaging modalities, including congenital heart disease, pulmonary hypertension, cardiotoxicity in oncology patients, and Covid-19 related heart issues. The company was incorporated in 2004 and is based in Toronto, Canada.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for VentriPoint Diagnostics Ltd., and the rating behind it. VPTDF last traded at $0.08; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for VentriPoint Diagnostics Ltd.. Starting points for VentriPoint Diagnostics Ltd.: EPS -$0.02, beta 0.17 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for VentriPoint Diagnostics Ltd.. VentriPoint Diagnostics Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for VentriPoint Diagnostics Ltd.. Trailing twelve-month EPS for VentriPoint Diagnostics Ltd. stands at -$0.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for VentriPoint Diagnostics Ltd.. VentriPoint Diagnostics Ltd. has reported as a listed company since 2010. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
VentriPoint Diagnostics Ltd. valued side by side against its closest peers. VentriPoint Diagnostics Ltd. is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold VentriPoint Diagnostics Ltd., and how their positions are changing. At a $13.1M market value, institutional positions materially move VentriPoint Diagnostics Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by VentriPoint Diagnostics Ltd. executives and directors. Shares of VentriPoint Diagnostics Ltd. have traded between $0.05 and $0.14 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming VentriPoint Diagnostics Ltd.. VentriPoint Diagnostics Ltd. is a $13.1M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming VentriPoint Diagnostics Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for VentriPoint Diagnostics Ltd.. Coverage tracks VentriPoint Diagnostics Ltd. within Medical - Devices (Healthcare). Press releases and market coverage, newest first.